6th Norwegian Cancer Symposium, Oslo, 4 to 6 December, 2017

Detailed program

The program consists of keynotes and lectures by invited scientists, oral presentations based on selected submitted abstracts, as well as poster presentations.

To submit an abstract for oral presentation in the plenary sessions, please create an account and then log in with the supplied password. For further details, please see the information for presenters.

The program is preliminary as of December 1, 2017 and is subject to change.

Monday 4 December

13.00 Welcome
13.15 Session 1 - Computational cancer genomics
Chair: Eivind Hovig
13.15 Keynote: Peter J. Park, Harvard Medical School
Structural alternations in cancer genomes
14.00 Break
14.20 Keynote: Ivo Gut, Centro Nacional de Análisis Genómico (CNAG)
The Pancancer study of the International Cancer Genome Consortium
15.10 Stian Knappskog, University of Bergen
Driver mutations in chemoresistant breast cancer
15.35 Rolf Skotheim, OUS, The Norwegian Radium hospital
Tumor heterogeneity in prostate cancer by multi-level genomics
15.55 Break
16.15 Keynote: Nitzan Rosenfeld, University of Cambridge
Liquid biopsies: expanding technologies and clinical applications of circulating tumour DNA
16.50 Ola Myklebost, University of Bergen
Using genomics and cell biology to find new treatment for orphan cancer
17.15 Thomas Berg, University Hospital of Northern-Norway
Lessons from routine clinical pathology: Implementation of deep sequencing in the diagnostics of lung, melanoma and gastrointestinal malignancies 
17.30 Break
18.30 City Hall Reception
20.00 End

Tuesday 5 December

09.00 Session 2 - Personalized Cancer Detection, Tumour Immunology and the microenvironment
Chair: June Myklebust
09.00 Keynote: Ash Alizadeh, Stanford University
Circulating Tumor DNA Analysis for Personalized Cancer Detection and Monitoring
09.45 Break
10.05 Günter Schmidt, Definiens AG
Discovery of novel predictive immune signatures using tissue phenomics
10.40 Els Verdegaal, Leiden University Medical Center
Neoepitope dynamics during T cell therapy
11.05 June Myklebust, OUS, The Norwegian Radium Hospital
Identification of targets for immune checkpoint blockade in B-cell lymphoma
11.25 Break
11.45 Randi Hovland, Haukeland University Hospital
Clonal hematopoiesis in donor cells developed into acute myeloid leukemia in the recipient after allogenic stem cell transplantation
12.05 Jorrit Enserink, OUS, The Norwegian Radium Hospital
Targeting the rewired protein interaction network of FLT3-ITD eradicates leukemic stem cells and overcomes FLT3 inhibitor resistance
12.25 Junbai Wang OUS, The Norwegian Radium Hospital
Whole-genome sequence analysis reveals roles of regulatory mutations in BCL6 and BCL2 in follicular lymphoma
12.45 Thomas Fleischer OUS, The Norwegian Radium Hospital DNA methylation at enhancers identifies distinct breast cancer lineages and features of therapy response
13.00 Lunch
14.15 Session 3 - Single cell analysis for disease trajectories and Liquid Biopsies, monitoring cancer genetics in body fluids
Chair: Leonardo Meza-Zepeda
14.15 Sten Eirik W. Jacobsen, University of Oxford
Unraveling the biology of normal and malignant hematopoietic stem cells at the single cell level
14.50 Heidi Namløs, OUS, The Norwegian Radium Hospital
Liquid biopsies; A non-invasive insight into the sarcoma genome
15.15 Break
15.50 Hilde Langseth, Cancer Registry of Norway
Serum RNAs as biomarkers of Cancer
16.15 Trine B. Rounge, Cancer Registry of Norway
Hypervariability in human papilloma virus - a cancer biomarker?
16.30 Poster session (with drinks/snacks)
19.00 Conference dinner

Wednesday 6 December

09.00 Session 4 - Clinical interpretation to guide precision medicine and diagnostics (translation and clinical genomics). Precision drugs, reality, predictions and combinations and New strategies for “personalized” clinical trials
Chair: Gunnar Sæter
09.00 Keynote: Ching C. Lau, Connecticut children's medical center 
Development and practice of precision medicine in pediatric oncology
09.45 Break
10.00 Edwin Cuppen, Hartwig medical foundation
National scale tumor whole genome sequencing for personalized cancer treatment
10.40 Gunhild Mælandsmo, OUS, The Norwegian Radium hospital
MetAction: Actionable Targets in Cancer Metastasis Experiences from the First Norwegian Study of NGS-Based Therapy Decisions in Advanced Cancer
11.20 Mev Dominguez Valentin, OUS, The Norwegian Radium Hospital
Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds
11.40 Geir Hetland, OUS / University of Oslo
The Agaricus blazei-Based Mushroom Extract, Andosan™, Protects against Intestinal Tumorigenesis in the A/J Min/+ Mouse
11.55 Closing Remarks

Norsk Hydro's Fund for Cancer Research